ATYR Relative Valuation
ATYR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATYR is overvalued; if below, it's undervalued.
Historical Valuation
aTyr Pharma Inc (ATYR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.80. The fair price of aTyr Pharma Inc (ATYR) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.83
Fair
-1.45
PE
1Y
3Y
5Y
Trailing
Forward
0.03
EV/EBITDA
aTyr Pharma Inc. (ATYR) has a current EV/EBITDA of 0.03. The 5-year average EV/EBITDA is -1.38. The thresholds are as follows: Strongly Undervalued below -5.28, Undervalued between -5.28 and -3.33, Fairly Valued between 0.57 and -3.33, Overvalued between 0.57 and 2.51, and Strongly Overvalued above 2.51. The current Forward EV/EBITDA of 0.03 falls within the Historic Trend Line -Fairly Valued range.
0.04
EV/EBIT
aTyr Pharma Inc. (ATYR) has a current EV/EBIT of 0.04. The 5-year average EV/EBIT is -1.32. The thresholds are as follows: Strongly Undervalued below -4.98, Undervalued between -4.98 and -3.15, Fairly Valued between 0.51 and -3.15, Overvalued between 0.51 and 2.34, and Strongly Overvalued above 2.34. The current Forward EV/EBIT of 0.04 falls within the Historic Trend Line -Fairly Valued range.
69.20
PS
aTyr Pharma Inc. (ATYR) has a current PS of 69.20. The 5-year average PS is 481.55. The thresholds are as follows: Strongly Undervalued below -1530.13, Undervalued between -1530.13 and -524.29, Fairly Valued between 1487.39 and -524.29, Overvalued between 1487.39 and 2493.22, and Strongly Overvalued above 2493.22. The current Forward PS of 69.20 falls within the Historic Trend Line -Fairly Valued range.
-1.35
P/OCF
aTyr Pharma Inc. (ATYR) has a current P/OCF of -1.35. The 5-year average P/OCF is -2.65. The thresholds are as follows: Strongly Undervalued below -6.43, Undervalued between -6.43 and -4.54, Fairly Valued between -0.76 and -4.54, Overvalued between -0.76 and 1.13, and Strongly Overvalued above 1.13. The current Forward P/OCF of -1.35 falls within the Historic Trend Line -Fairly Valued range.
-0.99
P/FCF
aTyr Pharma Inc. (ATYR) has a current P/FCF of -0.99. The 5-year average P/FCF is -1.99. The thresholds are as follows: Strongly Undervalued below -6.17, Undervalued between -6.17 and -4.08, Fairly Valued between 0.09 and -4.08, Overvalued between 0.09 and 2.18, and Strongly Overvalued above 2.18. The current Forward P/FCF of -0.99 falls within the Historic Trend Line -Fairly Valued range.
aTyr Pharma Inc (ATYR) has a current Price-to-Book (P/B) ratio of 1.01. Compared to its 3-year average P/B ratio of 2.21 , the current P/B ratio is approximately -54.23% higher. Relative to its 5-year average P/B ratio of 1.92, the current P/B ratio is about -47.38% higher. aTyr Pharma Inc (ATYR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -39.19%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -36.39% , the current FCF yield is about -100.00% lower.
1.01
P/B
Median3y
2.21
Median5y
1.92
-83.40
FCF Yield
Median3y
-39.19
Median5y
-36.39
Competitors Valuation Multiple
The average P/S ratio for ATYR's competitors is 78.26, providing a benchmark for relative valuation. aTyr Pharma Inc Corp (ATYR) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ATYR decreased by 77.13% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 190.00K.
The secondary factor is the Margin Expansion, contributed -35.08%to the performance.
Overall, the performance of ATYR in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is aTyr Pharma Inc (ATYR) currently overvalued or undervalued?
What is aTyr Pharma Inc (ATYR) fair value?
How does ATYR's valuation metrics compare to the industry average?
What is the current P/B ratio for aTyr Pharma Inc (ATYR) as of Dec 05 2025?
What is the current FCF Yield for aTyr Pharma Inc (ATYR) as of Dec 05 2025?
What is the current Forward P/E ratio for aTyr Pharma Inc (ATYR) as of Dec 05 2025?